

**EUROPEAN
CURRICULUM
VITAE**



PERSONAL INFORMATION

Name and Surname

MATTEO CHIURLO

PEC e-mail adress

Nationality

Date of birth

**EDUCATION AND
TRAINING**

Scientific Secondary-school diploma

Scientific Technologic Secondary School "ISIS A. Malignani Institute" (Udine)

Date Jul-2012

Master's degree in Medicine and Surgery – LM41

University of Udine (Udine)

Date 06/03/2019

Infectious Disease and Tropical Medicine Specialization degree

Vita Salute San Raffaele University– IRCCS San Raffaele Scientific Institute (Milan)

Date 30/10/2023

ALS Certificate - Advanced Life Support (Italian Resuscitation Council)

Obtained c/o IRCCS San Raffaele Institute (Milan)

Date 27/04/2022

**Sonography Training: "Corso di Perfezionamento in Ecografia Internistica"
(SIUMB)**

University of Pavia – (Pavia)

From 23/11/2022 – Ongoing

WORK EXPERIENCE

Participation in vaccination campaign for SARS-CoV-2

IRCCS San Raffaele Institute (Milan)

From 10/04/2021 to 31/08/2021

Physician, divisional on-call duty

Infectious Disease Unit - IRCCS San Raffaele Institute (Milan)

From 15/12/2021 to 30/06/2022

Physician, divisional on-call duty

Infectious Disease Unit - IRCCS San Raffaele Institute (Milan)

From 01/10/2022 to 31/10/2023

MOTHER TONGUE(S)	ITALIAN
OTHER LANGUAGES	ENGLISH
• Reading	PROFICIENT
• Writing	PROFICIENT
• Speaking	PROFICIENT
	GERMAN
• Reading	BASIC
• Writing	BASIC
• Speaking	BASIC
JOB-RELATED SKILLS	Clinical skills acquired in ward, outpatient and clinical consultancy settings in low- and high-intensity hospital wards. Clinical skills in complex patient management acquired in an emergency department setting. Training in diagnostics skills through the use of the ultrasound scanner.
COMPUTER SKILLS	Use of IT resources for writing, presentation and database creation (Word, Excel, PowerPoint, Access).
DRIVING LICENCE(S)	B category driving licence
ADDITIONAL INFORMATION	Professional qualification as a Doctor of Medicine obtained at University of Udine on 22/07/2019 Currently registered with the “Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri” (Milan) Date of registration 11/05/2021 - Registration no. 48023
PUBLICATIONS	Canetti D, Dell'acqua R, Riccardi N, Della Torre L, Bigoloni A, Muccini C, Bruzzesi E, Ranzenigo M, Chiurlo M, Racca S, Galli C, Castagna A, Tambussi G, Lazzarin A. Sars-Cov-2 Igg/Igm Rapid Test As A Diagnostic Tool In Hospitalized Patients And Healthcare Workers, At A Large Teaching Hospital In Northern Italy, During The 2020 Covid-19 Pandemic. New Microbiol. 2020 Oct;43(4):161-165. Epub 2020 Oct 31. Pmid: 33135083. Messina E, Danise A, Ferrari G, Andolina A, Chiurlo M, Razanakolona M, Barakat M, Israel RJ, Castagna A. Ribavirin Aerosol In The Treatment Of SARS-Cov-2: A Case Series. Infect Dis Ther. 2021 Dec;10(4):2791-2804. Doi: 10.1007/S40121-021-00493-9. Epub 2021 Jul 23. PMID: 34302258; PMCID: PMC8302211. Chiurlo M, Mastrangelo A, Ripa M, Scarpellini P. Invasive Fungal Infections In Patients With COVID-19: A Review On Pathogenesis, Epidemiology, Clinical Features, Treatment, And Outcomes. New Microbiol. 2021 Apr;44(2):71-83. PMID: 34240742. Muccini C, Galli L, Poli A, Chiurlo M, Ranzenigo M, Hasson H, Castagna A. Changes In Homeostatic Model Assessment For Insulin Resistance (HOMA-IR) Index In Treated HIV-1 Infected People On Virological Suppression Who Switched To A Different Antiretroviral Regimen. J Acquir Immune Defic Syndr. 2021 May 1;87(1):E169-E173. Doi: 10.1097/QAI.0000000000002632. PMID: 33492020. Pastori C, Galli L, Siracusano G, Spagnuolo V, Muccini C, Mastrangelo A, Bruzzesi E, Ranzenigo M, Chiurlo M, Castagna A, Lopalco L. Serum Igg1 And Igg4 Could Contribute To Partial Control Of Viral Rebound In Chronically HIV-1-Infected Patients. AIDS. 2021 Aug 1;35(10):1549-1559. Doi: 10.1097/QAD.0000000000002944. PMID: 33993130. Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.

Drug Des Devel Ther. 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. eCollection 2022. PMID: 35783200.

Bruzzesi E, Raccagni AR, Canetti D, Galli L, Badalucco F, Mori G, Chiurlo M, Guffanti M, Castagna A, Nozza S. Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series. J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.04.037. Epub 2022 Apr 26. PMID: 35483454

Mori G, Strano M, Chiurlo M, Bossolasco S, Cernuschi M, Castagna A. Probable West Nile Virus hepatitis: Case report. IDCases. 2023 Jul 5;33:e01841. doi: 10.1016/j.idcr.2023.e01841. PMID: 37502652; PMCID: PMC10368814.

Ripa M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastrangelo A, Muccini C, Monti G, De Luca G, Landoni G, Dagna L, Clementi M, Rovere Querini P, Ciceri F, Tresoldi M, Lazzarin A, Zangrillo A, Scarpellini P, Castagna A; COVID-BioB study group. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021 Mar;27(3):451-457. doi: 10.1016/j.cmi.2020.10.021. Epub 2020 Oct 24. PMID: 33223114; PMCID: PMC7584496.

Ripa M, Galli L, D'Angelo A, Apruzzi L, Palumbo D, Campochiaro C, Tassan Din C, Danise A, Da Prat V, Vitali G, Brugliera L, Poli A, Monardo R, Monti G, Baccellieri D, De Cobelli F, Clementi M, Iannaccone S, Dagna L, Rovere-Querini P, Ciceri F, Tresoldi M, Zangrillo A, Scarpellini P, Castagna A; COVID-BioB Study Group. High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19. Open Forum Infect Dis. 2022 Sep 2;9(9):ofac454. doi: 10.1093/ofid/ofac454. PMID: 36168552; PMCID: PMC9511118.

Spagnuolo V, Guffanti M, Galli L, Poli A, Querini PR, Ripa M, Clementi M, Scarpellini P, Lazzarin A, Tresoldi M, Dagna L, Zangrillo A, Ciceri F, Castagna A; COVID-BioB study group. Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2021 May 17;11(1):10699. doi: 10.1038/s41598-021-89270-9. Erratum for: Sci Rep. 2020 Dec 4;10(1):21291. PMID: 34001918; PMCID: PMC8127505.

Spagnuolo V, Guffanti M, Galli L, Poli A, Querini PR, Ripa M, Clementi M, Scarpellini P, Lazzarin A, Tresoldi M, Dagna L, Zangrillo A, Ciceri F, Castagna A; COVID-BioB study group. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2020 Dec 4;10(1):21291. doi: 10.1038/s41598-020-78039-1. Erratum in: Sci Rep. 2021 May 17;11(1):10699. PMID: 33277573; PMCID: PMC7718220.

Quanto dichiarato è conforme alle disposizioni degli artt. 46 e 47 del DPR 445/00; il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 GDPR 679/16 ed ai sensi del D.Lgs. 101/2018

Milan, 07/11/2023